Dr. Daniel Neumann, M.D.
Pediatrics (Pediatrics Physician)
At a glance
- In the NPI registry since
- 2015
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
IL license 125067233
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 9 companies reported 12 payments worth $469 in total to this clinician.
| Tris Pharma Inc | $268 |
|---|---|
| Collegium Pharmaceutical, Inc. | $53.67 |
| Acadia Pharmaceuticals Inc | $30.67 |
| Supernus Pharmaceuticals, Inc. | $23.77 |
| Corium, LLC | $23.21 |
| Sanofi-aventis U.S. LLC | $18.43 |
| Cranial Technologies, Inc | $17.73 |
| Pfizer Inc. | $16.85 |
| Food and Beverage | $469 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $394,111 in research payments for these studies, mostly to the institutions running them.
- A phase 2 randomized doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants
Pfizer Inc. - Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06252285 - Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Sanofi Pasteur Inc. · Active, not recruiting · NCT06824194 - A phase 3A, observer-blind, randomized, controlled study to evaluate t
GlaxoSmithKline, LLC. - A phase ii, single-blind, randomized, controlled study to evaluate the
GlaxoSmithKline, LLC. - Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06397768
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.